We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Western Blotting Processors Market to Reach USD 329 Million by 2028

By LabMedica International staff writers
Posted on 20 Sep 2018
Print article
Image: The western blotting processors market is expected to grow from USD 200 million to USD 329 million by 2028 (Photo courtesy of Next Advance).
Image: The western blotting processors market is expected to grow from USD 200 million to USD 329 million by 2028 (Photo courtesy of Next Advance).
The western blotting processors market is projected to grow at a CAGR of 5.1% from an estimated USD 200 million in 2018 to just under USD 329 million towards the end of 2028, driven partly by the increasing cases of HIV globally as western blot is a confirmed test that can detect anti-HIV antibodies in blood serum samples.

These are the latest findings of Future Market Insights (Valley Cottage, NY, USA), a market intelligence and consulting firm.

The western blotting processors market is highly competitive with the top companies accounting for a major portion of the global sales. Leading companies are acquiring smaller companies and expanding their production capacities to capture a larger share of the global market. Companies in the western blotting processors market are leveraging the available market opportunities to launch their products in full gear in the global market. Product registration followed by commercialization is accelerating the product launch process and creating healthy competition in the global market for western blotting processors. Additionally, manufacturers of western blotting processors are setting up production facilities in other countries to benefit from access to cheap labor and resource expertise, and realign their distribution and customer-oriented strategies.

However, advanced automated western blotting devices, such as high performance western blotting transfer systems, are more highly priced in comparison to their traditional counterparts, thus restricting their adoption in most developing economies. In regions with high labor costs, cheap traditional western blotting processors are still being used to perform protein tests, resulting in time-consuming and high labor cost-inducing processes. Additionally, the global western blotting processors market has witnessed the launch of a few advanced products in recent years. Further, results obtained from the western blotting process are not completely reliable or consistent and the devices are required to be updated regularly for producing more efficient and reliable results. These factors are expected to pose a challenge to the revenue growth of the global western blotting processors market.

Related Links:
Future Market Insights

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.